<DOC>
	<DOCNO>NCT01432951</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics enzastaurin metabolite native Chinese patient advance and/or metastatic solid tumor lymphoma . Information side effect may occur also collect . Treatment disease main purpose study . This Phase 1 study enzastaurin native Chinese patient advance and/or metastatic solid tumor lymphoma . Patients receive daily dos enzastaurin 14 day , stop dose 3 day PK sampling , resume dose Day 18 . Patients may allow receive enzastaurin approximately 2 4 week day 18 provide opportunity patient 's oncologist assess potential benefit patient continue receive enzastaurin safety extension phase . There plan duration extension phase ; patient allow continue receive enzastaurin disease progression reason discontinuation per investigator 's assessment .</brief_summary>
	<brief_title>A Study Enzastaurin Chinese Patients With Advanced and/or Metastatic Solid Tumors Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Have give write informed consent Have histologic cytologic diagnosis cancer ( solid tumor lymphoma ) clinical radiologic evidence locally advance and/or metastatic disease lifeprolonging therapy exists . ( Note : patient glioblastoma , hematologic malignancy [ except lymphoma ] exclude study . ) Male female patient reproductive potential must use approved contraceptive method , appropriate ( example , intrauterine device , birth control pill , barrier device ) 3 month discontinuation study treatment . Women childbearing potential must negative serum pregnancy test within 7 day prior study enrollment . Have performance status 0 2 Eastern Cooperative Oncology Group ( ECOG ) scale , investigator 's opinion , suitable participation study Have discontinue previous therapy cancer , include chemotherapy , radiotherapy , anticancer hormone therapy , investigational therapy least 30 day prior study entry ( 6 week mitomycinC nitrosoureas ) , recover acute effect therapy If patient hormonerefractory prostate cancer , study doctor discus patient drug would allow continue receive study Have adequate organ function , include : Bone Marrow Reserve : absolute neutrophil count ( ANC ) great equal 1.5 × 10^9/L prior treatment , platelet great equal 100 × 10^9/L , hemoglobin great equal 10 g/dL . Patients may receive erythrocyte transfusion achieve hemoglobin level discretion investigator . Patients may allow erythropoietin choice per standard care . Hepatic : bilirubin within 1.5 time upper limit normal ( ULN ) , alanine transaminase , aspartate transaminase less equal 2.5 time ULN less equal 5 time ULN liver metastasis know Renal : serum creatinine less equal 1.5 mg/dL Electrolytes : Patients may enter study , investigator 's opinion , electrolyte disorder , include potassium le 3.4 mEq/L , calcium le 8.4 mg/dL , magnesium le 1.2 mEq/L , may appropriately manage stabilized time laboratory evaluation leadin day . If electrolyte stabilize time , patient discontinue study . Patients hypercalcemia exclude . Have estimate life expectancy , judgment investigator , permit patient complete PK phase least 1 cycle safety extension phase ( patient participate safety extension phase ) Have receive treatment within 28 day first dose study drug experimental agent non cancer indication receive regulatory approval indication Patients glioblastoma hematologic malignancy lymphoma exclude study . Patients central nervous system ( CNS ) metastases ( unless patient complete successful local therapy CNS metastases corticosteroid least 4 week start study therapy ) exclude . In absence clinical suspicion brain metastasis , screen compute tomography ( CT ) magnetic resonance imaging ( MRI ) scan enrollment require . Serious concomitant systemic disorder , include active infection , incompatible study ( discretion investigator ) Have history human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C infection Have serious cardiac condition Have abnormal electrocardiogram ( ECG ) finding , discretion investigator Use medication know cause certain change electrocardiogram ( ECG ) reading Have history unexplained syncope ( faint passing ) within last year , know family history unexplained sudden death Have complete gastrectomy significant gastrointestinal disease , investigator 's opinion , may significantly impact drug absorption Are receive total parenteral nutrition Are able swallow tablet Are woman breast feeding , lactate , pregnant Are allergic enzastaurin Are receive herbal regimen Drugs herbal supplement know potent moderate inhibitor inducer cytochrome P450 ( CYP ) 3A specifically exclude . Foods know potent moderate inhibitor CYP3A ( example , grapefruit , grapefruit juice , Seville oranges , Seville orange juice ) also specifically exclude study . In addition , starfruit starfruit juice exclude PK phase study . Drugs narrow therapeutic window also know substrate CYP2C9 , CYP2C8 , CYP2C19 , CYP3A exclude Have average weekly alcohol intake exceed 21 unit per week ( men ) 14 unit per week ( woman ) unwilling stop alcohol consumption leadin day completion collect sample study drug measurement ( 1 unit = 12 oz 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) Use drug abuse , evidence history and/or positive finding urinary drug screening , unless prescribe physician ( example , narcotic pain medication ) The investigator think participate reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>